Franklin Resources
BDTX icon

Franklin Resources’s Black Diamond Therapeutics BDTX Stock Holding History

Franklin Resources’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-300,107
Closed -$7.28M – 2020
2021
Q1 		$7.28M Hold
300,107
– – ﹤0.01% 1043
2020
Q4 		$9.62M Buy
300,107
+7
+0% +$230 ﹤0.01% 967
2020
Q3 		$9.07M Buy
300,100
+30
+0% +$913 ﹤0.01% 935
2020
Q2 		$8.52M Hold
300,070
– – ﹤0.01% 900
2020
Q1 		$7.49M Buy
+300,070
New +$9.13M 0.01% 849

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Franklin Resources's BDTX Position: Q2 2021 in Review

Franklin Resources sold out of Black Diamond Therapeutics (BDTX) in Q2 2021, closing a stake of 300,107 shares — an estimated $7.28M sold.

Franklin Resources first reported a position in BDTX in Q1 2020 and held it in 5 quarters. The position peaked at $9.62M in Q4 2020. 102 funds tracked by Wall St. Rank hold BDTX as of Q2 2021.

  • Franklin Resources reported no remaining Black Diamond Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Franklin Resources sold 300,107 Black Diamond Therapeutics shares in Q2 2021, an estimated $7.28M.
  • Franklin Resources first reported a position in Black Diamond Therapeutics in Q1 2020 and held it in 5 quarters.
  • Franklin Resources's Black Diamond Therapeutics position peaked at $9.62M in Q4 2020.
  • 102 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2021.

Based on Franklin Resources's 13F filing for Q2 2021, filed 13 Aug 2021.